NASDAQ:DRIO • US23725P3082
The current stock price of DRIO is 9.09 USD. Today DRIO is up by 2.13%. In the past month the price decreased by -11.66%. In the past year, price decreased by -31.74%.
ChartMill assigns a technical rating of 0 / 10 to DRIO. When comparing the yearly performance of all stocks, DRIO is a bad performer in the overall market: 87.63% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to DRIO. The financial health of DRIO is average, but there are quite some concerns on its profitability.
On March 9, 2026 DRIO reported an EPS of 2.96 and a revenue of 5.01M. The company beat EPS expectations (159.22% surprise) and missed revenue expectations (-13.34% surprise).
10 analysts have analysed DRIO and the average price target is 18.36 USD. This implies a price increase of 101.98% is expected in the next year compared to the current price of 9.09.
For the next year, analysts expect an EPS growth of 45.22% and a revenue growth -17.32% for DRIO
Over the last trailing twelve months DRIO reported a non-GAAP Earnings per Share(EPS) of -5.24. The EPS increased by 74.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.52% | ||
| ROE | -49.53% | ||
| Debt/Equity | 0.41 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 20.65 | 30.754B | ||
| WAY | WAYSTAR HOLDING CORP | 14.9 | 4.71B | ||
| DOCS | DOXIMITY INC-CLASS A | 14.63 | 4.551B | ||
| HTFL | HEARTFLOW INC | N/A | 1.891B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.099B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 230.84 | 1.081B | ||
| CERT | CERTARA INC | 13.08 | 1.06B | ||
| TDOC | TELADOC HEALTH INC | N/A | 975.848M | ||
| SDGR | SCHRODINGER INC | N/A | 939.856M | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 6.02 | 770.783M | ||
| PHR | PHREESIA INC | 16.9 | 683.689M | ||
| HSTM | HEALTHSTREAM INC | 26.58 | 602.174M | ||
| EVH | EVOLENT HEALTH INC - A | 11.26 | 337.153M |
View all stocks in the Health Care Technology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company is headquartered in New York City, New York and currently employs 196 full-time employees. The company went IPO on 2013-03-08. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
IPO: 2013-03-08
DARIOHEALTH CORP
322 W 57Th St. #33B
New York City NEW YORK 10019 US
CEO: Erez Raphael
Employees: 199
Phone: 16466654667
DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company is headquartered in New York City, New York and currently employs 196 full-time employees. The company went IPO on 2013-03-08. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
The current stock price of DRIO is 9.09 USD. The price increased by 2.13% in the last trading session.
DRIO does not pay a dividend.
DRIO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
DARIOHEALTH CORP (DRIO) currently has 199 employees.
You can find the ownership structure of DARIOHEALTH CORP (DRIO) on the Ownership tab.
The outstanding short interest for DARIOHEALTH CORP (DRIO) is 1.29% of its float.